Leonardo DRS DRS 深 沪
已收盘 08-01 16:00:00 美东时间
41.67
+0.070
+0.17%
华盛通- 最 高42.42
- 今 开40.87
- 成交量 218.67万股
- 最 低 40.22
- 昨 收 41.60
- 总市值 110.84亿
- 52周最高 49.31
- 市盈率 静 52.37
- 换手率 0.82%
- 52周最低 25.82
- 委 比 -17.77%
- 总股本 2.66亿
- 历史最高 49.31
- 量 比 1.22
- 振 幅 5.29%
- 历史最低 8.93
- 每 手 1
- 风险率 6.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Morgan Stanley Maintains Equal-Weight on Leonardo DRS, Raises Price Target to $47
Morgan Stanley analyst Kristine Liwag maintains Leonardo DRS (NASDAQ:DRS) with a Equal-Weight and raises the price target from $44 to $47.
07-31 23:31
Leonardo DRS shares are trading lower. The company reported Q2 financial results.
Leonardo DRS shares are trading lower. The company reported Q2 financial result...
07-31 01:39
Leonardo DRS declares $0.09 dividend
Leonardo DRS (NASDAQ:DRS) declares $0.09/share quarterly dividend, in line with previous. Forward yield 0.78% Payable Sept. 23; for shareholders of record Aug. 20; ex-div Aug. 20. See DRS Dividend Sc...
07-30 22:05
Leonardo DRS Raises FY2025 Adj EPS Guidance from $1.02-$1.08 to $1.06-$1.11 vs $1.08 Est; Raises FY2025 Sales Guidance from $3.425B-$3.525B to $3.525B-$3.600B vs $3.521B Est
Leonardo DRS (NASDAQ:DRS) raises FY2025 Adj EPS guidance from $1.02-$1.08 to $1.06-$1.11 vs $1.08 analyst estimate. Raises FY2025 sales outlook from $3.425 billion-$3.525 billion to $3.525 billion-$3.600 billion vs
07-30 19:32
Insights Ahead: Leonardo DRS's Quarterly Earnings
Leonardo DRS (NASDAQ:DRS) is set to give its latest quarterly earnings report o...
07-30 01:01
SA Asks: Which stocks could benefit from the Golden Dome project?
Which stocks could benefit from the Trump administration's proposed multi-billion dollar Golden Dome defense project? We asked Seeking Alpha analysts Leo Nelissen, Dhierin Bechai and Cappuccino Financ...
07-28 02:00
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.
07-19 02:17
强生(JNJ.US)突破性疗法获优先审评资格 超80%患者肿瘤完全消失
今日，强生(JNJ.US)宣布，美国FDA已授予其创新膀胱内药物释放系统TAR-200新药申请(NDA)优先审评资格，用于治疗对卡介苗(BCG)无应答的高危非肌层浸润性膀胱癌(HR-NMIBC)伴原位瘤患者。
07-18 07:58
Defense Stocks Head Into Earnings At Record Highs — Is The Boom Just Beginning?
Defense stocks are rallying on Trump's record defense bill, but Q2 earnings will test whether companies can deliver on high expectations.
07-17 03:43
